Energy International Development

Energy International Development Co., Ltd. is a Hong Kong-based investment holding company and a wholly-owned subsidiary of Sino Biopharmaceutical Limited. The company serves as a strategic investment vehicle within the Charoen Pokphand (CP) Group's healthcare ecosystem. It is most notably recognized for its 2020 strategic investment of $515 million in Sinovac Life Sciences, which granted it a 15.03% equity interest and supported the global development of the CoronaVac COVID-19 vaccine. Through its parent company, Energy International Development is linked to a vast portfolio of pharmaceutical products in therapeutic areas such as oncology, liver disease, and respiratory health. The entity plays a crucial role in financing and managing high-stakes partnerships and acquisitions for one of China's largest pharmaceutical conglomerates. Its operations are centered on enhancing the research and production capabilities of its biotech affiliates.